OAC
DYN icon

OMERS Administration Corp’s Dyne Therapeutics DYN Stock Holding History

OMERS Administration Corp’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,600
Closed -$833K – 951
2024
Q2 		$833K Buy
+23,600
New +$686K 0.01% 573

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

OMERS Administration Corp's DYN Position: Q3 2024 in Review

OMERS Administration Corp sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 23,600 shares — an estimated $833K sold.

OMERS Administration Corp first reported a position in DYN in Q2 2024 and held it in 1 quarter. The position peaked at $833K in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • OMERS Administration Corp reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • OMERS Administration Corp sold 23,600 Dyne Therapeutics shares in Q3 2024, an estimated $833K.
  • OMERS Administration Corp first reported a position in Dyne Therapeutics in Q2 2024 and held it in 1 quarter.
  • OMERS Administration Corp's Dyne Therapeutics position peaked at $833K in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on OMERS Administration Corp's 13F filing for Q3 2024, filed 13 Nov 2024.